Demystifying the Maze: Centralized vs. National Procedures for Rare Disease Drug Registration in the EU

Demystifying The Maze Centralized vs. National Procedures for Rare Disease Drug Registration in the EU Introduction The European market presents a compelling opportunity for US pharma and biotech companies developing life-changing therapies for rare diseases.¬† Engaged patient communities and sophisticated healthcare systems create a fertile ground for innovation. However, navigating the intricacies of the European […]